HeimLSTA • NASDAQ
add
Lisata Therapeutics Inc
Við síðustu lokun
2,94 $
Dagbil
2,72 $ - 3,07 $
Árabil
1,87 $ - 4,20 $
Markaðsvirði
24,07 m. USD
Meðalmagn
15,10 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 5,85 m. | -11,42% |
Nettótekjur | -4,72 m. | 12,53% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -0,55 | 15,38% |
EBITDA | -5,80 m. | 11,46% |
Virkt skatthlutfall | 16,92% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 25,83 m. | -40,41% |
Heildareignir | 28,98 m. | -39,92% |
Heildarskuldir | 3,88 m. | -29,43% |
Eigið fé alls | 25,10 m. | — |
Útistandandi hlutabréf | 8,60 m. | — |
Eiginfjárgengi | 1,00 | — |
Arðsemi eigna | -45,69% | — |
Ávöxtun eigin fjár | -53,50% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -4,72 m. | 12,53% |
Handbært fé frá rekstri | -5,40 m. | 23,13% |
Reiðufé frá fjárfestingum | 9,43 m. | 46,54% |
Reiðufé frá fjármögnun | -23,00 þ. | 83,80% |
Breyting á handbæru fé | 4,01 m. | 608,63% |
Frjálst peningaflæði | -4,32 m. | 24,29% |
Um
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Stofnsett
1980
Höfuðstöðvar
Vefsvæði
Starfsfólk
26
